Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(35 sites)
United States
California Cancer Associates for Research & Excellence, Inc., Encinitas, California California Cancer Associates for Research & Excellence, Inc., Fresno, California Rhode Island Hospital, Providence, Rhode Island Mary Crowley Cancer Research, Dallas, Texas MD Anderson Cancer Center - Oncology, Houston, Texas NEXT Oncology, San Antonio, Texas Canada
The Ottawa Hospital Cancer Centre, Ottawa University Health Network - Princess Margaret Cancer Centre, Toronto Japan
National Cancer Center Hospital - Dept of Gastroenterology, Chūōku National Cancer Center Hospital East, Kashiwa-shi Saitama Cancer Center, Kitaadachi-gun Cancer Institute Hospital of JFCR, Kōtoku Aichi Cancer Center Hospital, Nagoya Kindai University Hospital, Osakasayama-shi Shizuoka Cancer Center, Sunto-gun Kanagawa Cancer Center, Yokohama South Korea
Kyungpook National University Chilgok Hospital, Daegu National Cancer Center, Goyang-si Seoul National University Bundang Hospital, Seongnam Asan Medical Center, Seoul Samsung Medical Center, Seoul Seoul National University Hospital, Seoul Severance Hospital, Yonsei University Health System, Seoul Spain
Hospital Clinic de Barcelona, Barcelona Hospital del Mar, Barcelona Hospital HM Nou Delfos, Barcelona Hospital Universitari Vall d'Hebron - VHIR, Barcelona Hospital Universitario Reina Sofia, Córdoba ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat Centro Integral Oncologico Clara Campal, Madrid Hospital Universitario 12 de Octubre, Madrid Hospital Universitario Fundacion Jimenez Diaz, Madrid Hospital Universitario Quironsalud Madrid - NEXT Oncology, Madrid Complejo Hospitalario Universitario de Santiago, Santiago de Compostela Hospital Universitario Virgen del Rocio, Seville